Identification of cytochromes P450 involved in the human liver microsomal metabolism of the thromboxane A2 inhibitor seratrodast (ABT- 001)

Drug Metabolism and Disposition

Volumn 25, Issue 1, 1997, Pages 110-115

  Kumar, Gondi N ^a   Dubberke, Erik ^b   Rodrigues, A David ^b   Roberts, Ellen ^b   Dennisen, Jon F ^b  

^a ABBOTT LABORATORIES   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; SERATRODAST; THROMBOXANE A2 RECEPTOR BLOCKING AGENT;

ARTICLE; ASTHMA; CHEMICAL REACTION KINETICS; DRUG METABOLISM; HUMAN; HUMAN TISSUE; LIVER MICROSOME; PRIORITY JOURNAL;

ANTI-ASTHMATIC AGENTS; ANTIBODIES; B-LYMPHOCYTES; BENZOQUINONES; CYTOCHROME P-450 ENZYME SYSTEM; ENZYME INHIBITORS; HEPTANOIC ACIDS; HUMANS; ISOENZYMES; KINETICS; MICROSOMES, LIVER; SUBSTRATE SPECIFICITY; THROMBOXANE A2;

EID: 0031012650     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. A. D. Rodrigues: Comparison of levels of aldehyde oxidase with cytochrome P450 activities in human liver in vitro. Biochem. Pharmacol. 48, 197-200 (1994).
2. T. Omura and R. Sato: The carbon monoxide-binding pigment of liver microsomes. Anal. Biochem. 239, 2370-2378 (1964).
3. A. D. Rodrigues and R. A. Prough: Induction of cytochromes P4501A1 and P4501A2 and measurement of catalytic activities. Methods Enzymol. 206, 423-431 (1991).
4. M. Maurice, S. Emiliani, I. Dalet-Beluche, J. Derancourt, and R. Lange: Isolation and characterization of cytochrome P450 of the IIA subfamily from human liver microsomes. Eur. J. Biochem. 200, 511-517 (1991).
5. P. K. Srivatsava, C.-H. Yun, P. H. Beaune, C. Ged, and F. P. Guengerich: Separation of human liver microsomal tolbutamide hydroxylase and (S)-mephenytoin 4′-hydroxylase cytochrome P450 enzymes. Mol. Pharmacol. 40, 69-79 (1991).
6. S. A. Wrighton, J. C. Stevens, G. W. Becker, and M. VandenBranden: Isolation and characterization of human liver cytochrome P4502C19: correlation between 2C19 and S-mephenytoin 4′-hydroxylation. Arch. Biochem. Biophys. 306, 240-245 (1993).
7. 14C]dextromethorphan. Anal. Biochem. 219, 309-320 (1994).
8. S. Belman: The fluorimetric determination of formaldehyde. Anal. Chim. Acta 29, 120-126 (1963).
9. W. Tassaneeyakul, M. E. Veronese, D. J. Birkett, F. J. Gonzalez, and J. O. Miners: Validation of 4-nitrophenol as an in vitro substrate probe for human liver CYP2E1 using cDNA expression and microsomal kinetic techniques. Biochem. Pharmacol. 46, 1975-1981 (1993).
10. A. D. Rodrigues, D. J. Mulford, R. D. Lee, B. W. Surber, M. J. Kukulka, J. L. Ferrero, S. B. Thomas, M. S. Shet, and R. W. Estabrook: In vitro metabolism of terfenadine by a purified recombinant fusion protein containing cytochrome P4503A4 (CYP3A4) and NADPH-P450 reductase. Drug Metab. Dispos. 23, 765-773 (1995).
11. S. Chen, R. Knox, A. D. Lewis, F. Friedlos, P. Workman, P. S. K. Deng, M. Fung, D. Ebenstein, K. Wu, and T.-M. Tsai: Catalytic properties of NAD(P)H:quinone acceptor oxidoreductase: study involving mouse, rat, human, and mouse-rat chimeric enzymes. Mol. Pharmacol. 47, 934-939 (1995).
12. S.-L. Wang, J.-D. Huang, M.-D. Lai, and J.-J. Tsai: Detection of CYP2C9 polymorphism based on the polymerase chain reaction in Chinese. Pharmacogenetics 5, 37-42 (1995).
13. M. E. Veronese, C. J. Doecke, P. I. Mackenzie, M. E. McManus, J. O. Miners, D. L. Rees, R. Gasser, U. A. Mayer, and D. J. Birkett: Site-directed mutation studies of human liver cytochrome P-450 isoenzymes in the CYP2C subfamily. Biochem. J. 289, 533-538 (1993).
14. J. R. Halpert, F. P. Guengerich, J. R. Bend, and M. A. Correia: Selective inhibitors of cytochrome P450. Toxicol. Appl. Pharmacol. 125, 163-175 (1994).
15. D. J. Newton, R. W. Wang, and A. Y. H. Lu: Cytochrome P450 inhibitors: evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metab. Dispos. 23, 154-158 (1995).
16. J. Maenpaa, N. Sigusch, H. Raunio, T. Syngelma, P. Vuorela, H. Vuorela, and O. Pelkonen: Differential inhibition of coumarin 7-hydroxylase activity in mouse and human liver microsomes. Biochem. Pharmacol. 45, 1035-1042 (1993).
17. J. L. Raucy and J. M. Lasker: Human P450 enzymes associated with the mephenytoin 4-hydroxylation polymorphism. In "Human Drug Metabolism: From Molecular Biology to Man" (E. H. Jeffery, ed.), pp. 23-31. CRC Press, Boca Raton, FL, 1993.
18. N. A. Helsby, S. A. Ward, R. E. Howells, and A. M. Breckenridge: In vitro metabolism of the biguanide antimalarials in human liver microsomes: evidence for a role of the mephenytoin hydroxylase (P450 MP) enzyme. Br. J. Clin. Pharmacol. 30, 287-291 (1990).
19. M. A. Leo, J. M. Lasker, J. L. Raucy, C.-I. Kim, M. Black, and C. S. Lieber: Metabolism of retinol and retinoic acid by human liver cytochrome P450IIC8. Arch. Biochem. Biophys. 269, 305-312 (1989).
20. M. P. Lopez-Garcia, P. M. Dansette, and D. Mansuy: Thiophene derivatives as new mechanism-based inhibitors of cytochromes P-450: inactivation of yeast-expressed human liver cytochrome P-450 2C9 by tienilic acid. Biochemistry 33, 166-175 (1994).
21. S. A. Wrighton and B. J. Ring: Inhibition of human CYP3A catalyzed 1′-hydroxy midazolam formation by ketoconazole, nifedipine, erythromycin, cimetidine and nizatidine. Pharm. Res. 11, 921-924 (1994).
22. J. O. Miners, K. J. Smith, R. A. Robson, M. E. McManus, M. E. Veronese, and D. J. Birkett: Tolbutamide hydroxylation by human liver microsomes. Biochem. Pharmacol. 37, 1137-1144 (1986).
23. J. W. Harris, A. Rahman, B.-K. Kim, F. P. Guengerich, and J. M. Collins: Metabolism of taxol by human hepatic microsomes and liver slices: participation of cytochrome P450 3A4 and an unknown P450 enzyme. Cancer Res. 54, 4026-4035 (1994).
24. A. Rahman, K. R. Korzekwa, J. Grogan, F. J. Gonzalez, and J. W. Harris: Selective biotransformation of taxol to 6α-hydroxytaxol by human cytochrome P450 2C8. Cancer Res. 54, 5543-5546 (1994).
25. T. Shimada, H. Yamazaki, M. Mimura, Y. Inui, and F. P. Guengerich: Interindividual variation in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J. Pharmacol. Exp. Ther. 270, 414-423 (1994).
26. J. L. Raucy, M. R. Wester, E. Aramsombatdee, and J. M. Lasker: Purification and characterization of human liver CYP2C19: an S-mephenytoin 4-hydroxylase. In "Proceedings of Symposium on Microsomes and Drug Oxidations," July 18-21, 1994, Toronto, pp. 1-281, 1994.
27. A. B. Okey: Enzyme induction in the cytochrome P-450 system. Pharmacol. Ther. 45, 241-298 (1990).
28. K. Venkatesan: Pharmacokinetic drug interactions with rifampicin. Clin. Pharmacol. 22, 47-65 (1992).
29. S. A. Wrighton and J. C. Stevens: The human hepatic cytochromes P450 involved in drug metabolism. Crit. Rev. Toxicol. 22, 1-21 (1992).